ResearchBCYC

BCYC: FY25 Deep Dive

Ddrillr ResearchOriginal research

Published Sep 3, 20261 min read

Summary

Bicycle Therapeutics FY25 at $73M. NI $-219M; EPS $-3.16.

FY25 revenue $73M; OI $-247M; NI $-219M; EPS $-3.16.

Bicycle Therapeutics FY25 (Dec 31, 2025) at $73M revenue. OpInc $-247M; NI $-219M; EPS $-3.16. Biotech — Oncology.